Clinical Trial Update: A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major [Phase 1]

View source ↗

Summary

Phase 1 trial to evaluate gene-modified autologous hematopoietic stem cells (BD211) for treating β-thalassemia major is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia Major

Drugs mentioned

• BD211

Snippet

Sponsor: Shanghai BDgene Co., Ltd. | Conditions: β-thalassemia | Phase 1 | Status: RECRUITING